Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Priority to GT200500312ApriorityCriticalpatent/GT200500312A/en
Publication of GT200500312ApublicationCriticalpatent/GT200500312A/en
SE PRESENTA UN MEDICAMENTO QUE COMPRENDE DE FORMA CONJUNTA O SEPARADA EL GLICOPIRROLATO (A); Y (B) QUE PUEDA SER UN COMPUESTO DE FORMULA (I) EN SAL LIBRE O FORMA SOLVATADA; O UN COMPUESTO DE FORMULA (II), EN FORMA LIBRE O EN FORMA DE SOLVATO; PARA ADMINISTRACION SIMULTANEA, SECUENCIAL O SEPARADA PARA EL TRATAMINETO DE ENFERMEDADES INFLAMATORIAS U OBSTRUCTIVAS DE LAS VIAS RESPIRATORIAS. SE DESCRIBEN TAMBIEN COMPOSICIONES FARMACEUTICAS QUE CONTIENEN (A) Y (B).A MEDICINAL PRODUCT IS PRESENTED THAT INCLUDES IN A JOINT OR SEPARATE FORM THE GLYCOPIRROLATE (A); AND (B) THAT IT CAN BE A FORMULA COMPOUND (I) IN FREE SALT OR SOLVATED FORM; OR A FORMULA COMPOUND (II), IN FREE FORM OR IN SOLVATE FORM; FOR SIMULTANEOUS, SEQUENTIAL OR SEPARATE ADMINISTRATION FOR THE TREATMENT OF INFLAMMATORY OR OBSTRUCTIVE DISEASES OF RESPIRATORY ROADS. THERE ARE ALSO DESCRIBED PHARMACEUTICAL COMPOSITIONS CONTAINING (A) AND (B).
DERIVATIVES OF 5-PHENYL-4-METHYL-TIAZOL-2-IL-AMINA AS INHIBITORS OF KINASA ENZYMES PHOSFATIDILINOSITOL 3 (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE RESPIRATORY ROUTES
Compounds derived from piperidino-dihydrothienopyrimidines; pde4 inhibitors; pharmaceutical composition comprising them; and use in the treatment of disorders or diseases of the respiratory or gastrointestinal routes, as well as inflammatory diseases of the joints or eyes, among others.
DERIVATIVES OF 2, 6-QUINOLINILO, A PHARMACEUTICAL PREPARATION THAT CONTAINS THEM AND ITS EMPLOYMENT IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF DEPENDENT DISEASES OF INTEGRINES ALFA4BETA1 AND / OR ALFA4BETA7